Malekzadeh Sara, Heidari Mahmood Reza, Razavi Bibi Marjan, Rameshrad Maryam, Hosseinzadeh Hossein
School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Pharmacodynamics and Toxicology, School of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Iran J Basic Med Sci. 2019 Dec;22(12):1476-1482. doi: 10.22038/IJBMS.2019.13992.
Olanzapine, an atypical antipsychotic, causes weight gain and metabolic disorders in humans. Safranal, one of the active components of (saffron), has been shown to have anti-obesity, lipid and blood pressure lowering and anti-diabetes effects. In this investigation, the effect of safranal on metabolic disorders induced by olanzapine was studied.
Fourty-two female Wistar rats were divided into 7 groups of 6 animals. The two groups were selected as controls, which received olanzapine and safranal solvents, respectively. The third group treated by olanzapine 5 mg/kg. Groups 4, 5 and 6 treated by olanzapine 5 mg/kg plus safranal (2.5, 5 and 10 mg/kg) and the last group received safranal 10 mg/kg. The injections were performed intraperitoneally for 14 days and on the 15 day the rats were killed and their serum were collected to measure metabolic factors including glucose, insulin, triglyceride, total cholesterol and HDL cholesterol. Leptin level in plasma was also measured. Mean systolic blood pressure was measured using tail cuff method at the end of study. The rats were weighed every other day and amount of food consumed was measured daily.
Olanzapine significantly elevated body weight, food intake, fasting blood glucose, TG, leptin, and mean systolic blood pressure (MSBP). It also significantly decreased HDL cholesterol blood level. Safranal significantly improved all these complications at three doses.
Based on the results of this study, safranal is thought to be used as an effective combination in controlling metabolic complications caused by olanzapine.
奥氮平是一种非典型抗精神病药物，可导致人体体重增加和代谢紊乱。藏红花醛是藏红花的活性成分之一，已被证明具有抗肥胖、降低血脂和血压以及抗糖尿病的作用。在本研究中，研究了藏红花醛对奥氮平诱导的代谢紊乱的影响。
42只雌性Wistar大鼠分为7组，每组6只。选择两组作为对照组，分别接受奥氮平和藏红花醛溶剂。第三组用5mg/kg奥氮平治疗。第4、5和6组用5mg/kg奥氮平加藏红花醛（2.5、5和10mg/kg）治疗，最后一组接受10mg/kg藏红花醛。腹腔注射14天，在第15天处死大鼠并收集血清，以测量包括葡萄糖、胰岛素、甘油三酯、总胆固醇和高密度脂蛋白胆固醇在内的代谢因子。还测量了血浆中的瘦素水平。在研究结束时，使用尾袖法测量平均收缩压。每隔一天称重大鼠体重，每天测量食物摄入量。
奥氮平显著提高了体重、食物摄入量、空腹血糖、甘油三酯、瘦素和平均收缩压（MSBP）。它还显著降低了血液中高密度脂蛋白胆固醇水平。藏红花醛在三个剂量下均显著改善了所有这些并发症。
基于本研究结果，藏红花醛被认为可作为控制奥氮平引起的代谢并发症的有效联合用药。
